Drugs.com - Clinical Trials

AZD0780, a Novel Oral PCSK9 Inhibitor, Demonstrated Significant LDL Cholesterol (LDL-C) Reduction in PURSUIT Phase IIb Trial

31 March 2025 -- Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin...

Apr 1, 2025 - 02:06
 0
AZD0780, a Novel Oral PCSK9 Inhibitor, Demonstrated Significant LDL Cholesterol (LDL-C) Reduction in PURSUIT Phase IIb Trial
31 March 2025 -- Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin...
Read More

Tags:

Previous Article

Trump tariffs jolt Asian automakers — Toyota likely set for most pain

Next Article

Lilly's Lepodisiran Reduced Levels of Genetically Inherited Heart Disease Risk F...

Related Posts

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

BioRestorative Receives FDA Fast Track Designation for ...

Mar 1, 2025  0

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

U.S. FDA Accepts Gilead’s New Drug Applications for Twi...

Feb 27, 2025  0

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Nurix Announces U.S. FDA Orphan Drug Designation Grante...

Mar 18, 2025  0